Skip to main content
OpenTrials
Completed

NCT Number: NCT02044575

Clock Genes in Patients With Refractory Septic Shock (SeptiClock) - Pilot Study

Despite large efforts trying to improve diagnostic and therapy of sepsis have been made over the last decade (e.g. initiation of the Surviving Sepsis Campaign, defining evidence based sepsis therapy bundles) the mortality of septic shock remains high and causes high socioeconomical burden of disease.

The purpose of this pilot study is to evaluate the design and conduct of a projected full scale clinical trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Anesthesiology and Intensive Care Medicine, Campus Charité Mitte and Campus Virchow - Klinikum, Charité- Universitätsmedizin

Berlin, 13353, Germany

About this study

A functional clock is required for induction of several proinflammatory genes, not shown in septic patient settings, yet.

Clock genes are involved in modulating the activity of several transcription factors that are important regulators of immune functions (e.g. HIF1-α, STAT1, STAT3, and NF-κB) (Bellet MM et al., 2013).

Furthermore, polymorphisms such as rs7221412, a common polymorphism near period homolog 1 (PER1), was associated with the timing of activity rhythms and also showed a suggestive time-dependent relationship with both cerebral cortex and monocytes PER1 expression and an association with time of death (Lim ASP et al., 2012).

This explorative project is a pilot study. First data are generated for the assessment of the circadian system in patients with septic shock.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients with age 18 years and above,
  • Patient at intensive care units (8i, 9i and 1i at Charité - University Medicine Berlin , Campus Virchow- Klinikum),
  • Septic shock (ACCP/SCCM (American College of Chest Physicians/Society of Critical Care Medicine) consensus definitions) AND Norepinephrine dosage of >0.3 μg/kg/min for at least 2 hours

Exclusion criteria

  • Pregnant or lactating female patient,
  • Participation in another interventional study (30 days before study inclusion and during study participation),
  • Acute leucemia,
  • Severe leukocytosis (>50,000/nl),
  • Severe thrombocytopenia (<5,000/nl),
  • Autoimmune disease with systemic medication of ≥10 mg prednisolone equivalent or previous transplantation,
  • Patients receiving interferon therapy (last 14 days),
  • Patients with known hypersensitivity GM-CSF or known antibodies against GM-CSF, yeast-derived products or any component of the study medication,
  • Ongoing (concomitant) chemotherapy or radiotherapy for malignancy,
  • Acute pulmonary embolism or acute myocardial infarction within last 72 hours,
  • Cardiopulmonary resuscitation within last 7 days,
  • Moribund patient (life expectancy <72 hrs.),
  • Presence of a do-not-resuscitate or do-not-intubate order,
  • Known human immunodeficiency virus (HIV) infection or chronic viral hepatitis
  • Lacking willingness to save and hand out data within the study
  • Accommodation in an institution due to an official or judicial order
  • The informed consent of the patient or the subject's legally acceptable representative can´t be obtained in time
  • Patient has a power of attorney or patient's provision, where he/she refuses participation in any clinical trial

Treatment and study plan

Primary outcomes

  1. Assessment of circadian regulation

    Time frame: These parameters are measured during intensive care unit stay, for a maximum of 3 days

    Circadian regulation by expression of clock genes

Secondary outcomes

  1. Time on mechanical ventilation

    Time frame: They are followed up until the end of intensive care unit stay - or, for a maximum of 28 days

  2. Intensive care unit length of stay

    Time frame: Participants will be followed for the duration of intensive care stay, an expected average of 4 weeks

  3. Hospital length of stay

    Time frame: Participants will be followed for the duration of intensive care stay, an expected average of 5 weeks

  4. Simplified Acute Physiology Score (SOFA II)

    Time frame: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.

  5. Sequential Organ Failure Assessment (SOFA)

    Time frame: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.

  6. Therapeutic Intervention Scoring System (TISS-28)

    Time frame: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.

  7. Mortality

    Time frame: 6 months after intensive care unit discharge

  8. Light frequencies

    Time frame: Light frequencies are measured until the end of intensive care unit stay - or, for a maximum of 28 days

  9. Light levels (lux)

    Time frame: Light levels are measured until the end of intensive care unit stay - or, for a maximum of 28 days

  10. Cortisol

    Time frame: This parameter is measured in ng/ml during intensive care unit stay, for a maximum of 3 days

  11. Melatonin

    Time frame: This parameter is measured in pg/ml during intensive care unit stay, for a maximum of 3 days

  12. Quality of life

    Time frame: Up to 3 and 6 months

    Quality of life is measured by SF-36 questionnaire

  13. Cognitive function

    Time frame: Up to 3 and 6 months

    Cognitive function is measured by Repeatable Battery for the Assessment of Neuropsychological Status

  14. Multiplex-Genexpression analysis

    Time frame: These parameters are measured during intensive care unit stay, for a maximum of 3 days

    Ncounter neuroinflammation and micro rna panel are analysed

Other outcomes

  1. Nagalase enzyme activity

    Time frame: This parameter is measured at the beginning of the investigation

    Nagalase Enzyme activity is expressed in nmol/min per Milliliter. Analysis is evaluated with the perioperative Nagalase results of 10 patients in the clinical trial Phydelio (EudraCT-No 2008-007237-47).

  2. Venous return

    Time frame: This parameter is measured at the beginning of the investigation

    Venous return will be assessed after ICU admission by venous return pressure gradient (dVR)

Sponsors and collaborators

Lead sponsor

Claudia Spies

Other

Registry information

Important dates

Study start
2014
Primary completion
2018
Study completion
2019
First posted
Jan 24, 2014
Registry last updated
Jun 16, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.